Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial

Respiratory Research

Pierluigi Paggiaro³  Andrea Rossi⁴  Dario Olivieri⁶  Leonardo Fabbri¹  Nunzio Crimi²  Gabriele Nicolini⁷  Alberto Papi⁵ 

[1] Section of Respiratory Diseases, University of Modena, Modena, Italy;Department of Internal and Specialistic Medicine, Section of Respiratory Diseases, University of Catania, Catania, Italy;Cardio-Thoracic and Vascular Department, University of Pisa, Pisa, Italy;Pulmonary Unit, University/General Hospital of Verona, Verona, Italy;Research Center on Asthma and COPD, University of Ferrara, Via Savonarola 9, 44100, Ferrara, Italy;Department of Clinical Sciences, University of Parma, Parma, Italy;Medical Affairs Department, Chiesi Farmaceutici, Parma, Italy

关键词: Salmeterol;    Formoterol;    Fluticasone;    Extrafine;    Beclomethasone;   

Others  :  796705
DOI  :  10.1186/1465-9921-13-54

 received in 2012-03-27, accepted in 2012-06-14,  发布年份 2012

【 摘 要 】

Background

Asthma guidelines suggest that therapy can be reduced once asthma is controlled. Despite these recommendations, asthmatic patients are seldom stepped down in clinical practice, and questions remain about when and how to reduce asthma therapy. The purpose of the present study was to evaluate lung function and asthma control in patients who were stepped down from the highest recommended dose of inhaled corticosteroid/long acting β₂ agonist combination therapy.

Methods

This was a prospective, randomised, controlled, two-arm parallel group study. Asthmatic patients who were fully controlled with a high daily dose (1000/100 μg) of fluticasone/salmeterol were randomly assigned to 6 months of open-label treatment with either 500/100 μg fluticasone/salmeterol Diskus daily or 400/24 μg extrafine beclomethasone/formoterol pMDI daily. The primary outcome was the change in morning peak expiratory flow (PEF) values between baseline and the end of treatment. The secondary outcomes included asthma control and exacerbation frequency.

Results

Four hundred twenty-two patients were included in the analysis. The PEF values remained above 95% of the predicted values throughout the study. The end-study morning PEF rates showed equivalence between the groups (difference between means, 2.49 L/min; 95% CI, -13.43 to 18.42). No changes from baseline were detected in PEF and forced expiratory volume in 1 second measured at the clinics, in the symptom scores or in the use of rescue medication. Asthma control was maintained in 95.2% of the patients at 6 months. No significant differences between the groups were detected in any other parameter, including exacerbation frequency and adverse events.

Conclusions

Stepping down patients whose asthma is controlled with the highest recommended dose of fluticasone/salmeterol to either 500/100 μg fluticasone/salmeterol daily or 400/24 μg extra-fine beclomethasone/formoterol daily provides comparable maintenance of lung function and asthma control.

Trial registration

clinicaltrials.gov NCT00497237

【 授权许可】

   
2012 Papi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

Figure 5 .

【 参考文献 】

• [1]Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention, revised 2009. www.ginasthma.org webcite
• [2]Gibson PG, Powell H, Ducharme FM: Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev 2005, (4):CD005076.
• [3]O'Byrne PM, Naya IP, Kallen A, Postma DS, Barnes PJ: Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest 2008, 134:1192-1199.
• [4]Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE: GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004, 170:836-844.
• [5]Chung KF, Caramori G, Adcock IM: Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 2009, 65:853-871.
• [6]Woolcock A, Rubinfeld AR, Seale JP, Landau LL, Antic R, Mitchell C, Rea HH, Zimmerman P: Thoracic Society of Australia and New Zealand, Asthma management plan. Med J Aust 1989, 151:650-653.
• [7]Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, Jenkins CR: Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta(2)-agonist. Respir Med 2010, 104:1110-1120.
• [8]Diette GB, Patino CM, Merriman B, Paulin L, Riekert K, Okelo S, Thompson K, Krishnan JA, Quartey R, Perez-Williams D, Rand C: Patient factors that physicians use to assign asthma treatment. Arch Intern Med 2007, 167:1360-1366.
• [9]Fowler SJ, Currie GP, Lipworth BJ: Step-down therapy with low-dose fluticasone salmeterol combination or medium dose hydrofluoroalkane 134a-beclomethasone alone. J Allergy Clin Immunol 2002, 109:929-935.
• [10]Godard P, Greillier P, Pigearias B, Nachbaur G, Desfourgeres JL, Attali V: Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study. Respir Med 2008, 102:1124-1131.
• [11]Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M: Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 2006, 117:563-570.
• [12]Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, Wise RA, American Lung Association Asthma Clinical Research Centers: Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007, 356(20):2027-2039.
• [13]Koenig SM, Ostrom N, Pearlman D, Waitkus-Edwards K, Yancey S, Prillaman BA, Dorinsky P: Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down". J Asthma 2008, 45(8):681-687.
• [14]Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM: Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007, 29:682-689.
• [15]Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM, ICAT SE study group: Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007, 62:1182-1188.
• [16]GOLD Report Executive Summary: Global Strategy for Diagnosis, Management, and Prevention of COPD. December 2009. GOLD - Global Initiative for Chronic Obstructive Lung Disease home pagehttp://www.goldcopd.org webcite
• [17]Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL: What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 1999 Jul, 14(1):23-27.
• [18]Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997, 337(20):1405-1411.
• [19]Foresi A, Mastropasqua B, Chetta A, D'Ippolito R, Testi R, Olivieri D, Pelucchi A: Step-down compared to fixed-dose treatment with inhaled fluticasone propionate in asthma. Chest 2005, 127:117-124.
• [20]Fardon T, Haggart K, Lee DK, Lipworth BJ: A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007, 101:1218-1228.
• [21]IMS Health - Retail Sales Data.
• [22]Fabbri LM, Nicolini G, Olivieri D, Papi A: Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother 2008, 9:479-490.
• [23]Clearie KL, Jackson CM, Fardon TC, Williamson PA, Vaidyanathan S, Burns P, Lipworth BJ: Supervised step-down of inhaled corticosteroids in the community–an observational study. Respir Med 2011, 05:558-565.